AB Science will host a live webcast on masitinib in Progressive Forms of Multiple Sclerosis on Friday March 06, 2020

Paris, March 05, 2020, 6.30pm

AB Science will host a live webcast on masitinib in
Progressive Forms of Multiple Sclerosis on Friday March 06, 2020

AB Science SA (NYSE Euronext – FR0010557264 – AB) is hosting a live webcast on March 06, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis disclosed on February 20th, and the role that masitinib may play in treating these disorders.

The webcast will feature presentations by four Key Opinion Leaders

• Patrick Vermersch, MD, PhD (University of Lille, France), European KOL in multiple sclerosis
• Friedemann Paul, MD (Charité-Universitätsmedizin Berlin), European KOL in multiple sclerosis
• Robert Fox (Mellen Center for Multiple Sclerosis at Cleveland Clinic, USA), American KOL in multiple sclerosis
• Olivier Hermine, MD, PhD (Hospital Necker Paris, France), President of scientific committee of AB Science and member of the French Académie des Sciences

These key opinion leaders will provide:

• An overview of the current treatment options in progressive forms of multiple sclerosis.
• An explanation of masitinib differentiation which is driven by the drug’s mechanism of action which targets the innate immune system via mast cells and microglia.
• A discussion of the results from the recently reported Phase 2B/3 masitinib clinical trial in progressive forms of MS.

The presentation will be followed by a Q&A session with the key opinion leaders and management of AB Science.

Masitinib is a tyrosine kinase inhibitor designed to selectively target mast cells and macrophages, through inhibition of c-Kit, Lyn, Fyn, and MCSFR-1 kinases, which may have broad applicability in neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), multiple sclerosis and potentially Alzheimer’s disease. On February 20, AB Science announced that its Phase 2B/3 trial with oral masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis met its primary endpoint with masitinib at the 4.5 mg/kg/day dose (p=0.0256).